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1. Introduction
Physicians responsible for patient care focus on readily available clinical and trending labo‐
ratory data to help direct the patient’s clinical course and evaluate efficacy of therapy. Most
clinicians fail to incorporate newer parameters of tumor response such as tumor growth rate
when evaluating patient treatment response. Available now, is a wealth of dynamic growth
parameters that shed new light on tumor biology and should be used in clinical decision-
making.
What follows is in part a review of former paradigms of prostate tumor growth. Later, focus
is directed to newer techniques to assist in evaluating targeted drug effects on the kinetics of
prostate and other cancers. The discussion introduces the concept of tumor or marker specif‐
ic growth rate (SGR) and challenges historical results obtained by use of the classic tumor or
marker doubling time (PSA-DT).
As we proceed with this discussion, a mobile device App for hand-held computers includ‐
ing the iPhone, iPad, or iPod is presented. This conveniently facilitates a more sophisticated
tumor and marker analysis at the bedside or in the clinic.
2. Historical perspective of tumor growth kinetics, exponential and
Gompertzian kinetics
Though there is occasional homage paid to Gompertzian tumor growth, for practical pur‐
poses, when we care for patients, tumors are frequently undergoing exponential expansion.
© 2013 Tisman; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In the absence of tumor mutation or perturbation by therapy the growth rate of exponential‐
ly growing tumors is constant. Rarely, there may be periods of interrupted growth.
Gompertzian growth [1, 2, 3] is best described by a sigmoid-shaped curve. At tumor initia‐
tion growth is occult, slow and remains subclinical for several years. A second phase is the
rapid, clinically apparent exponential phase lasting for a few years followed by the slower
terminal growth phase as the tumor approaches 35-40 doublings representing a volume ap‐
proaching 1000 cc or a tumor diameter of 10 cm Figure 1. The duration of tumor growth
from inception is several years and for three quarters of that period the tumor is clinically
undetectable. At the time of discovery, the oncologist is attending to the last quarter of tu‐
mor growth.
Figure 1. Note the differences between the exponential and Gompertzian growth curves. The lethal burden of tumor
is approximately 1000 cc or ~35-40 doublings. In the clinic when tumors reach 0.5-1 cm in diameter (30 doublings or
109 cells) they are measurable and follow the exponential growth curve, the steeper the slope the larger the tumor
specific growth rate (SGR). Nonetheless, many feel that when looking at the entire lifespan of malignant tumors (over
several years) tumor growth may better be described by Gompertzian kinetics [3].
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3. Exponential growth
In 1934 Mottram [4, 5] reported work on the rat tar wart. Tar warts are tar-carcinogen in‐
duced neoplasms of the skin starting 75-100 days after the continuous painting of the rat’s
neck with tar. Histologically, some warts appear benign while others are clearly malignant.
Using the tar wart tumor growth model, Mottram was the first to describe tumor expansion
as exponential. Exponentially growing tumors graphically produce straight lines by plotting
linear time on the x-axis versus the log (at any base) of either tumor area, tumor cell number,
tumor volume or tumor diameter on the y-axis see Figure 2.
Figure 2. Friberg, Collins, Spratt, Steel, Schwartz affirmed that in the clinic, an exponential growth pattern adequately
described tumor growth for most patients. A semi-log plot of tumor diameter vs. time illustrates the linear relationship
characteristic of exponential growth.
Twenty years later Laird [6, 7] reported on the growth of transplanted tumors in the rat. Un‐
der her specific laboratory conditions, most tumor growth could be described in terms of the
Gompertzian model. Her experiments lead her to accept that for her laboratory model; most
transplantable, rapidly growing tumors could be described in Gompertzian terms.
Studies of tumor growth in clinic patients have been described in terms of both exponential
and Gompertzian models. Nevertheless, several investigators reported data that was incon‐
sistent with the Gompertzian model for the majority of their patients. These authors engag‐
ed routine imaging of both metastatic and primary pulmonary lesions in an attempt to
resolve whether exponential growth could be confirmed in the clinic. Friberg, Collins,
Spratt, Steel, Schwartz [8, 9, 10, 11, 12,13] affirmed that in the clinic, an exponential growth
pattern adequately described tumor growth for most patients Figures 2, 3.
Describing Prostate Cancer Dynamics: Second Look at PSA-Doubling Time and PSA-Specific Growth Rate
http://dx.doi.org/10.5772/53179
179
4. The tumor marker as a surrogate for tumor growth exemplified by PSA
and prostate cancer
4.1. PSA Velocity (PSA-V)
PSA-V is the rate of change in serum PSA over time. PSA-V = 1/2 ((PSA2-PSA1/t1 in years) +
(PSA3 – PSA2/t2 in years)), where PSA1 is the first, PSA2 the second and PSA3 the third PSA
measurement. Time represents the interval (in years) between PSA measurements. It is rec‐
ommended that three PSA measurements obtained over 24 months yields optimal accuracy.
A PSA-V exceeding 0.75 ng/ml/year is highly predictive of prostate cancer. PSA-V is more
Figure 3. Von Fournier et al. confirm a straight-line (by semi-log plot) relationship for patients with breast tumors sup‐
porting the model of exponential growth model.
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useful than PSA doubling time (PSA-DT) in the pretreatment setting to help identify those
men with life-threatening disease [14].
Studies confirm that the PSA tumor marker reflects prostate tumor growth and PSA dynam‐
ic changes are useful for predicting clinical outcome in several situations such as tumor re‐
currence and overall survival [15].
Klotz [16] reviewed the value of PSA as a tumor marker in patients with prostate cancer. He
noted that use of a single serum value of PSA is inadequate for predicting patient survival.
However, the PSA-V as ng/ml/yr. was a marker of disease biology. D’Amico [17] included
preoperative PSA-V in determining subsequent risk of death from prostate cancer in 1095
men with clinically localized prostate cancer that underwent prostatectomy and radiation
therapy [18]. A PSA-V >2 ng/ml/yr the year before prostatectomy, was associated with
lymph node metastases, an advanced pathologic stage, and high-grade disease. This thresh‐
old level of PSA-V was associated with a significantly shortened time to recurrence, death
from prostate cancer, and death from any cause. Strikingly, men with a PSA rise of >2.0
ng/ml had prostate cancer-specific mortality rates nine times those with a PSA-V <2 ng/ml.
4.2. Tumor marker Doubling Time (DT)
Miyamoto [19] studied the growth of hepatic metastases in colorectal cancer patients. He es‐
tablished that a tumor marker could accurately reflect tumor volume and its changes. Using
the CEA tumor marker he reported an almost equal and parallel correlation between CEA
doubling time and hepatic tumor volume doubling time.
PSA-DT Figure 4 is the time it takes for the serum PSA to double. Evidence indicates PSA-
DT closely mirrors prostate tumor volume doubling time. Kato et al. in 2008 [20] undertook
an attempt to correlate prostate tumor volume to serum PSA level. Kato’s group calculated
that for each ng/ml increment of serum PSA, there was a 0.302 cc increase in total tumor vol‐
ume and a 0.7% increase in relative tumor volume. Total tumor volume in cc was given as
V(cc) = 3.476 + 0.302 X PSA (ng/ml) while the percent tumor volume Volume(%) = 11.331 +
0.704 X PSA (ng/ml).
Babaian et. al. [21] reported that multivariate regression analysis of tumor volume as a func‐
tion of PSA, grade and stage demonstrated that log PSA had the strongest association with
tumor volume. Tanaka [22] reported that among significant preoperative and postoperative
parameters, calculated cancer volume remained an independent predictive parameter in
multivariate analysis (P <0.01). Tumor volume, as calculated by preoperative parameters,
was an independent predictor of biochemical recurrence in patients who had undergone
radical prostatectomy. Vollmer et al. [23] used a compartmental model and first order kinet‐
ics to develop the calculation necessary to relate serum PSA to tumor volume. They found
that the resulting model was a good fit to the observed kinetic data of PSA measured after
biopsy or prostatectomy. The model also predicted a linear relationship between PSA and
the sum of volumes of benign and malignant tissues.
Until evidence to the contrary, it is assumed that similar to colorectal tumors and CEA, there
is a reasonable relationship between serum PSA and its kinetics allowing its use as a predic‐
tor of changes of prostate tumor volume and growth kinetics.
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An important point when using serum PSA in calculations is that an exact interval for test‐
ing remains controversial, some investigators stress that the interval between PSA-DT deter‐
minations should approach 3-6 months [24] to limit error due to random variation of PSA
values. Using a third generation highly sensitive PSA assay, our laboratory changes in PSA
are precise to the third decimal point and allow educated decision-making based on month‐
ly determinations.
Figure 4. This figure is a semi-log plot of logs PSA (y-axis) vs. time (x-axis) [26]. Note the linear relationship, indicating
that the rise of PSA values follows an exponential expansion of PSA.
Historically, PSA kinetics for watchful waiters included PSA-DT. A PSA-DT of >10 yr. can
be considered favorable; a PSA-DT of <3-4 yr. suggests a change in biology and considera‐
tion should be given to an alternative therapy [25]. PSA kinetics should always be combined
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with other diagnostics such as endorectal ultrasound; endorectal MRI, digital rectal exam
and repeat prostate biopsies approximately every 6-12 months.
4.3. PSA-DT as a surrogate for drug activity
PSA is one of the major androgen receptor-dependent target genes [27], and clinical mon‐
itoring is used to detect early stage disease as well as the emergence of recurrent tumor
after  therapy  [28,  29,  30]  and  changes  mirror  changes  in  tumor  bulk  and  indicate  re‐
sponse to  drugs.  The graphic  representation of  PSA-DT is  illustrated and its  formula is
given in Figure 4 [26].
Kelloff et al. [31], reviewed the use of PSA-DT as a surrogate for tumor response to drugs in
patients with prostate cancer. They concluded that protocols that demonstrate significant
changes in PSA-DT might be used to support accelerated approval of newer therapies. There
is data to suggest PSA-DT in castrate resistant patients is predictive of outcome after chemo‐
therapy [32]. An important caveat is expressed by Newling’s review [33] of the subject
which concluded that though dynamic changes in the PSA such as PSA-DT are commonly
used in clinical trials of new drug therapies, PSA-DT might be affected by other factors in‐
cluding assay variations and false elevations of serum PSA caused by irritation of bladder
catheters, prostatitis and cystitis. A substantial incidence of transient elevations of PSA
(55%) was reported following combined external beam radiation and brachytherapy for
prostate cancer [34]. These complicating issues should always be considered before PSA-DT
is used to modify therapy.
Most recently, newer targeted and immunotherapies were found to produce paradoxical ef‐
fects on PSA kinetics. Newling [33] argues that PSA should therefore be used as a secondary
end point while overall survival still remains the gold standard in evaluating therapeutic ef‐
ficacy for patients with hormone refractory disease.
5. Defining PSA response
Investigators participating in new prostate cancer drug trials commonly define PSA re‐
sponse according to the Bubley guidelines [35] for phase II clinical trials in androgen-inde‐
pendent prostate cancer. The guidelines qualify the following categories of PSA: PSA
normalization, PSA <=0.2 ng/ml; PSA decrease, PSA decline ≥50%, confirmed by a second
PSA value 4 or more weeks later; PSA progression, PSA ≥25% increase over the baseline
(and an increase in the absolute value PSA level by at least 5 ng/mL). Though useful for
evaluating clinical trials, these PSA changes lack sensitivity when evaluating subtle drug ef‐
fects vs. prostate tumor growth [36,37, 38].
Therasse [39, 40], in his thesis reports on MRI and PSA as tools in a RECIST evaluation used
to define tumor response in prostate cancer patients with measurable soft tissue lesions.
When comparing MRI soft tissue responses to serum PSA changes, the correlation of PSA
and MRI showed agreement in 14 of the 20 (70%) patients.
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6. PSA-DT and Survival of prostate cancer patients
The importance of PSA-DT in predicting survival is illustrated by Freedland et al. [41] Fig‐
ure 5. This chart presents data for a group of patients experiencing biochemical recurrence
of PSA after prostatectomy. Under these circumstances, PSA-DT clearly defined prostate
cancer survival into four groups: 1) PSA-DT >=15 months, 2) PSA-DT 9-14 months 3) PSA-
DT 3-8.9 months, 4) PSA-DT <3 months. For this study, PSA-DT is clearly a surrogate for
prostate cancer-specific survival.
Figure 5.
7. PSA in the era of biologic and targeted therapy
A wealth of data establishes PSA as a marker of tumor aggressiveness, tumor stage, drug
response and survival. Controversy and concern persists regarding PSA’s role as a marker
of disease stabilization and response induced by cytostatic and immunotherapies when
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compared to cytolytic therapies. An evaluation of the difficulties surrounding PSA interpre‐
tation has been addressed [42].
Two vaccine trials, Sipuleucel-T (Provenge) [43, 44, 45] and the TRICOM PROSTVAC [46,
47] demonstrated a significant overall survival benefit without any consistent decline in
PSA, raising questions about the value of PSA response for non-hormonal, non-cytotoxic
therapies. In addition, wide fluctuations have been observed in PSA values due to a transi‐
ent effect of some drugs on PSA production seemingly independent of cell proliferation. The
independent, non-proliferative effect of drugs on PSA expression should be considered
when interpreting PSA response data. These aberrant PSA effects must be considered to‐
gether with imaging results and clinical evaluation of the patient. Nevertheless, it has been
consistent that post therapy a >50% PSA decline in pre-treatment PSA carries a significant
overall survival advantage [48, 35].
Kelly [48] reported on 110 assessable patients treated on seven sequential protocols at Me‐
morial Sloan-Kettering Cancer Center for hormone-refractory prostate cancer a statistically
significant survival advantage in 110 patients with >50% PSA decline (>25 months survival)
versus those without a 50% PSA decline (8.6 months survival). These results suggest that
post therapy PSA declines can be used as a surrogate end point to evaluate new agents in
hormone-refractory prostate cancer and criteria for response need prospective validation for
phase III trials. Smith et al. [49] showed that a PSA decline > 50% for at least 8 weeks result‐
ed in a longer mean survival time of 91 weeks versus 38 weeks for patients showing a small‐
er PSA reduction. An improved PSA response was associated with prolonged survival in
the TAX 327 study (Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Ad‐
vanced Prostate Cancer), with a median survival of 33 months when the PSA was normal‐
ized (<4 ng/mL) versus 15.8 months for an abnormal PSA [50, 51].
Heidenreich [52], the chair of the European Association of Urology oversaw the EAU 2012
Prostate Cancer Guidelines. He acknowledged that the PSA has been validated to be the
most clinically useful tumor marker of treatment failure following local therapy and of tu‐
mor response as well as of tumor progression following hormonal treatment.
8. Assessment of molecularly targeted, cytostatic or anti-angiogenic
agents
Bellmunt [53] and others expressed concern that PSA response criteria are not established to
properly evaluate molecularly targeted cytostatic or anti-angiogenic agents [54]; therefore,
certain drug-specific limitations may exist when using PSA or PSA-DT as an indicator of
progression or response. One clear example was noted in a study of sorafenib (Nexavar) in
castrate resistant prostate cancer, in which two patients with PSA progression were found to
have dramatic resolution of bony disease [55]. Therapy-associated PSA “surge” has been de‐
scribed after effective chemotherapy. PSA surge occurs with Samarium153 radiotherapy, an‐
drogen deprivation and chemotherapy and is generally transient. The surge may be due to
rapid lysis of prostate cancer cells thus spilling intracellular contents into the intravascular
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space [56]. Similarly, 10 of 16 patients who discontinued sorafenib and did not receive other
therapy demonstrated post-discontinuation PSA declines of 7–52% [57]. The review by Bell‐
munt [58, 59] notes that several targeted therapies caused prolongation of the PSA-DT as
well as significant suppression of PSA levels. The era of targeted therapy for prostate cancer
is just beginning and will require changes in how we interpret PSA kinetics.
9. Considerations in evaluating tumor growth effects of targeted therapies
Newer targeted therapies are often cytostatic or cytolentic (slowing proliferation) [60], re‐
sulting in disease stabilization, improved quality of life and extended survival. Examples of
such drugs include sorefinib (Nexavar) [61], axitinib (Inlyta) for renal cell carcinoma [62],
and mTOR inhibitors (everolimus (Afinitor) [63] and temsirolimus (Torisel)). Dasitinib
(Sprycel) and sorefinib (Nexavar) are active in prostate cancer. Dasatinib is active in chronic
granulocytic leukemia and GIST, inhibits BCR/ABL tyrosine kinase, KIT, PDGFR and Src ty‐
rosine kinase amongst other targets. The Src tyrosine kinase is instrumental in driving hor‐
mone-independent prostate cancers [64]. Dasatinib is active in castrate resistant prostate
cancer and may be administered safely with docetaxel [65, 66].
These newer therapies target not only the tumor cell but also modify the supporting stroma
and microvasculature. The cytostatic/cytolentic effects may leave the tumor dimensionally
intact, stable on imaging studies but with slower or absent growth for extended periods of
time. Some imaging techniques such as PET and MRI [67], able to quantify such metabolic
effects, may enhance clinical evaluation while CT images appear unchanged.
There is mounting evidence that stabilization of tumor growth significantly prolongs overall
survival to a degree similar to patients experiencing an objective response judged by RE‐
CIST or RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). This raises con‐
cern and new calls for modification of current RECIST categories to include new definitions
for targeted responses [68].
Simple reductions in PSA levels as defined by Bubley [35] have not yet been validated as a
surrogate end point for use in clinical trials of agents with novel mechanisms of action. As
indicated, cytotoxic chemotherapy alone, in combination with molecular-targeted agents, or
the sole use of targeted therapies, produces different and at times transient and paradoxical
changes in serum PSA and further studies are needed to further define this issue.
As questions have emerged concerning the utility of PSA levels as a surrogate end point, the
Prostate Cancer Clinical Trials Working Group reviewed the criteria for outcome measures
in clinical trials that evaluate systemic treatment for patients with progressive prostate can‐
cer. Recommendations conclude that PSA responses may be delayed in trials of non-cytotox‐
ic agents, and rising PSA levels in the absence of other signs of progression should not lead
to discontinuation of trials. This recommendation might lead to much consternation be‐
tween the patient and doctor where discussion of the latest PSA value is often the primary
subject during follow-up visits.
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10. Projected tumor size and projected PSA uncover hidden drug activity
Now that surrogacy of static values of PSA and PSA-DT is being questioned for targeted
therapies, new techniques of response evaluation are under study. One attempt to quanti‐
tate treatment efficacy redirects attention from PSA-DT to PSA-specific growth rate (PSA-
SGR) [69, 70, 71]. Generally ignored, projected tumor and marker value play a particularly
important role in uncovering and quantifying hidden, cytostatic or cytolentic drug effects.
Projected tumor volume or marker value is calculated prior to the initiation of therapy and
based on the specific growth rate constant (SGR) before the start of therapy. The projected
value is illustrated in Figure 7. This growth projection captures the inherent tumor SGR be‐
fore therapy and predicts what the outcome (projected tumor or marker volume/value)
would be at any future date in the absence of treatment or tumor mutation. Older cytotoxic
drugs, when effective, inhibit innate growth by programmed cell death and apoptosis re‐
sulting in autophagy and tumor cell lysis [60, 72]. This results in a measurable reduction of
tumor size. Interestingly, these drugs are often in part cytostatic or cytolentic and depending
on dose may result in stable disease. Keep in mind that prolongation of cytostatic or cytolen‐
tic suppression by any drug may eventually induce cytotoxicity and cell lysis [60] Figure 6.
Different combinations of static/lytic drug activity may result in reduced tumor/marker size
or complete tumor growth inhibition without clinically detectable change in tumor size. Un‐
der these circumstances, use of projected growth uncovers hidden suppression of prolifera‐
tion. A common clinical scenario occurs when during treatment, a tumor increases in size
but much less than projected. Unless the clinician calculates what the projected tumor size
should be, the true degree of tumor suppression is not appreciated Figure 7.
10.1. Mathematical relationships of exponentially growing tumors and projected tumor
marker or tumor size/volume
The mathematical expression for exponential expansion of growth is: Vt = V0eαt where the
tumor volume at time Vt is predictable and is the product of the starting tumor volume [V0]
and [e = 2.71828, the base of the natural logarithm raised to the product of the specific
growth rate constant α or (SGR) and the duration of growth Δt or (t1-t0)].
This is given as Vt = V0eSGR *∆t and mathematical rearrangement yields SGR =
ln( V 2V 1 )
t2− t1
Inhibitory drug effects slow SGR and are precisely quantifiable by calculating changes of SGR
and the tumor size before and after therapy. Tumor size after therapy should be compared to
the projected tumor size the same time after therapy. The current standard for clinical oncolo‐
gists is comparison of tumor size before and after therapy while neglecting comparison with
the projected tumor size. Differences between post therapy tumor size and the post therapy
projected tumor size are the clue to hidden responses that are almost never evaluated by the
clinical oncologist. These often-subtle differences between projected and post therapy tumor
sizes may reveal hidden growth stimulation (mutation or idiosyncratic drug effect) as well as
subtle growth inhibition, which may lead to prolonged clinical stability.
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The following relationships, extracted from Mehrara’s analysis [69,70,71] define projected
tumor volume: ∫tit △ SGR (t) * dt = ln( VnVi )− ln( VtVi ) where Vn = projected tumor volume, Vt =
volume of tumor at the time of response evaluation and Vi is the volume at the initiation of
therapy. The tumor response or TR = - ln(Vt/Vn) where Vt is the volume of treated tumor and
Vn is the hypothetical or projected tumor volume, both evaluated at the time of efficacy as‐
sessment. These relationships are the model for the growth kinetics of exponentially grow‐
ing tumors and generally require the use of at least a handheld computer to facilitate
evaluation in the clinic. This is further discussed in the appendix.
Figure 6. In vitro and in vivo, a clear distinction between cytostatic and cytolytic drugs does not exist. Low-dose cyto‐
lytic chemotherapy may exert cytostasis or so-called cytolentic slowing of cell proliferation leading to cell lysis, while
targeted therapy’s prolonged cytostatic metabolic effects (or large doses of targeted therapy) may induce cytolysis
and autophagy (autophagocytosis). Regardless of mechanism of cell inhibition, the SGR and the TR (treatment re‐
sponse) calculations clearly and objectively define and quantitate drug efficacy (TR value).
Picture a 4.0 cm diameter (14.1 cc) pulmonary metastasis. At the time of discovery two
months before the start of therapy the tumor was 3 cm (33.5 cc). The pre-therapy SGR for
this tumor = 1.46%/d (tumor volume was expanding by 1.46%/d). Sixty-one days of therapy
was administered and the tumor grew to 4.5 cm (47.7 cc). SGR decreased from 1.46%/d to
1%/d. Clinicians unaware of SGR and the projected tumor volume at this point might de‐
clare drug resistance however; the projected tumor volume was actually 80.6 cc and the tu‐
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mor reached only 47.7 cc. Even though the tumor grew, therapy was significantly effective
in slowing growth (59% of intrinsic tumor growth was inhibited)! The parameter for treat‐
ment efficacy, TR was +0.5. A positive value for TR means that therapy had some inhibitory
activity against the tumor, the larger the value the better. A negative value means therapy
was associated with growth stimulation. The value of TR is useful as an objective standard
comparator to help evaluate efficacy between different treatments.
Figure 7. Tumor size (volume) or Marker (PSA, PAP) Time Line
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Figure 7 illustrates potential tumor responses to drug treatment. Some of the responses such
as positive and negative deviation from the projected PSA value or projected tumor vol‐
ume are routinely overlooked in the clinic because projected sizes for these parameters
must be calculated in advance (projected volume is illustrated by the largest b-b green circle
at t2). SGR is calculated based on tumor or PSA growth between t0 and t1. Deviations from
projected values reveal subtle drug-tumor interactions. In the appendix we discuss straight‐
forward evaluation of all five-treatment outcome scenarios illustrated above by a hand-held
computer.
Until now, most attempts to capture drug effects vs. prostate tumors employed changes of
PSA-DT. However, Mehrara [70] presented newer assessments of PSA-DT compared to
PSA-SGR that cast doubt on the validity of that historic collection of work.
What follows is a general listing of consequences of drug-tumor interaction. These potential
tumor or marker responses Figures 6, 7 are important to understand because subtle changes
in tumor proliferation may be the only drug-induced tumor response and may go unnoticed
when evaluating targeted therapy by RECIST/RECIST 1.1 response criteria.
10.2. Targeted therapies might require SGR calculations to evaluate the full spectrum of
tumor response
Figures 6, 7 display tumor responses evaluable in the clinic. RESIST 1.1 criteria follow for
comparison.
1. Disease stabilization (complete inhibition of pre-therapy SGR)
The marker or tumor’s inherent growth rate is inhibited causing it or its surrogate marker
value to remain unchanged during therapy.
2. Uninterrupted growth
The tumor or marker continues its calculated pre-therapy growth rate without change dur‐
ing therapy. The growth noted in the surrogate marker or tumor after therapy is predictable
and equal to the projected tumor growth based on the calculated SGR before the start of
therapy.
3. Tumor “response” of varied degree (note: at the time of response evaluation the tumor
may be larger than the pre-therapy value)
Tumor or marker growth is inhibited and at post-therapy response evaluation the tumor or
its surrogate marker is less than the projected value. This response may be difficult to iden‐
tify since the tumor or its marker may have reached a size greater than before the start of
therapy however, tumor or marker post therapy is not as large as projected based on the
pre-therapy SGR Figure 7. A computer calculation comparing pre- and post-therapy SGR is
required to accurately quantify this response category. TR (treatment response) is easily cal‐
culable and offers an objective and continuous value for the degree of response. TR is used
as either a “tumor response” or “tumor marker response”, to quantitate the effect of thera‐
Advances in Prostate Cancer190
py. This continuous variable is useful to directly compare treatment efficacy between differ‐
ing therapies.
Mehrara [71] defined some limitations for the current use of treatment response including:
1) PR and CR as defined in RECIST and other methods are no longer of value for quantify‐
ing responses to cytostatic/cytolentic drugs. Combinations of cytolytic and cytostatic/cyto‐
lentic therapies add further difficulty to response interpretation. A further problem arises
when drugs are used at the extremes of dosing where tumor-killing activity may change
from cytostatic/cytolentic to cytolytic and vise versa. 2) Classically, no consideration is given
to the persistence of tumor SGR and or its inhibition during the course of therapy. Clinically,
this is a trap for the oncologist if response is based solely in terms of whether the tumor
marker or size is decreased at the end of therapy 3) The advantage of TR as a continuous
variable (as opposed to a discrete variable used to compartmentalize responses such as CR,
PR, SD) is that TR is a measurement of inhibitory (+TR) as well as accelerating (-TR) drug
effects and is directly comparable between therapies and independent of mechanism of drug
action.
A simple statement that the marker or tumor is larger post therapy is no longer adequate to
evaluate tumor responses.
4. The size of the tumor or its surrogate marker decreases after therapy.
This may be a partial or complete return to normal, manifest by partial or complete disap‐
pearance of tumor/marker abnormality.
5. Tumor acceleration and deceleration
Tumor acceleration occurs when the tumor or marker growth rate (SGR) after therapy is
greater than the pre-therapy or baseline SGR and SGR = (SGR after Rx − SGR before Rx) /
(t2−t1) is a negative value. Tumor growth rate acceleration is positive and may indicate the
presence of a tumor-accelerating mutation or an unexpected untoward drug effect.
Tumor deceleration occurs when SGR before therapy is greater than SGR after therapy and
is expressed as: SGR deceleration = (SGR after Rx −  SGR before Rx) / (t2− t1)  this is a nega‐
tive value.
The rate of change calculations are based on the pre-therapy calculated SGR and its rate of
change is calculated at the end of therapy and is expressed as: Acceleration or deceleration
of the SGR: ΔSGR / Δt . Or EDITOR use (SGR2-SGR1)/(T2-T1).
Note: In the presence of multiple tumor targets the sum of tumor diameters or volumes is
used as an approximation. Clonal heterogeneity (a mosaic of tumors growing at different
growth rates and or demonstrating a mixed response) may make some tumors inadequate
for analysis.
In 1999 an attempt to write a specific dogma evaluating tumor response resulted in the RE‐
CIST 1.0 criteria, later updated 2009 as RECIST 1.1 [73]. Note the absence of drug-response
based on the concept of projected tumor growth.
RECIST 1.1 criteria
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Complete Response (CR): Disappearance of all target lesions. Any pathological lymph no‐
des (whether target or non-target) must have reduction in short axis to <10 mm.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, tak‐
ing as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions,
taking as reference the smallest sum on study (this includes the baseline sum if that is the
smallest on study). In addition to the relative increase of 20%, the sum must also demon‐
strate an absolute increase of at least 5 mm. (Note: the appearance of one or more new le‐
sions is also considered progression).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to
qualify for PD, taking as reference the smallest sum diameters while on study.
Figure 8. Weber [74] reveals the difficulty of classifying real growth inhibition within the RECIST1.1 criteria of stable
disease. Real or suppressed tumor growth is illustrated by the pink growth curve only.
Weber noted that the RECIST 1.1 disease stabilization category does not differentiate be‐
tween a drug that slows tumor growth and the complete lack of drug effect Figure 8. The
RECIST 1.1 definition for disease progression is >5 mm absolute increase in size in addition
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to >20% increase compared with the nadir. In this figure, though all three tumors do not
meet the progressive disease criteria and thus would be termed stable, the growth of the
third was slowed by therapy. Though all three are termed stable, note the subtle difference
between the two tumors showing a continued and uninterrupted pre-therapy growth rate
(SGR), compared to the slowed growth rate of the tumor depicted by the red line. Surely
there is a drug effect vs. the red tumor. This active drug could be overlooked in spite of its
potential to increase survival if maintained for a sufficient period of time.
In a review of a group of patients treated with targeted therapies, Tourneau [75] revealed
clinical evidence where investigators overlooked subtle cytostatic/cytolentic (slowing of
SGR) drug activity Figure 6, 8. The group analyzed 50 patient participants in 18 targeted
therapy drug trials. Among the 44 patients who withdrew from study because of disease
progression according to the investigators’ assessment, 18 patients (41%) demonstrated a fa‐
vorable slowing trend in tumor specific growth rate. Among the 18, 5 had disease progres‐
sion according to RECIST 1.1 according to retrospective reassessment of on-study imaging
and occurrence of no new lesion during study treatment. Their preliminary evaluation con‐
cluded that a substantial proportion of patients treated with targeted agents were removed
from protocol in spite of possibly benefitting from therapy.
Ferte et al. [76] studied metastatic renal cell carcinoma patients treated with sorafenib (Nexa‐
var) and everolimus (Afinitor). Analysis of tumor SGR clearly revealed drug effects that
would have been missed had RECIST response criteria been applied. Tumor response was
assessed before, during, at the time of tumor progression and after drug discontinuation.
Tumor growth rate was computed by dividing tumor shrinkage by the time between two
related evaluations (% RECIST x 100 /day).
In two different patient populations (IGR and TARGET) tumor growth rate significantly de‐
creased following sorafenib (-23.6 vs. 20 (IGR) and -19 vs. 22 (TARGET)) and everolimus
(-5.2 vs. 30 (IGR)). The great majority of patients (IGR) had a decrease in the tumor growth
rate during vs. before therapy, regardless of the RECIST evaluation, both with sorafenib
(28/29) or everolimus (36/37). Growth rate after sorafenib or everolimus interruption was
significantly higher than at the time of progression in both settings (IGR) (14.6 vs. 31 and
17.9 vs. 32.1 respectively). No significant difference was observed between growth rate be‐
fore or after therapy for either sorafenib or everolimus (IGR). They concluded that SGR eval‐
uation revealed: 1) better evaluation of tumor response, regardless of RECIST criteria, 2) had
independent prognostic value, 3) the possibility that continuation of sorafenib or everolimus
after disease progression might be beneficial to patients by sustaining a continued suppres‐
sion of tumor growth.
The following section presents a model of tumor growth rate expressed as an executable al‐
gorithm in the form of an Apple App that quantitates subtle changes of tumor specific
growth rate (SGR).
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Figure 9. Following a patient’s tumor size often reveals subtle changes in the slope of the tumor measurement or
marker growth curve as revealed above. These subtle changes in growth rate are not associated with a significant de‐
crease of tumor size or marker value. As Le Tourneau et al. and Ferte et al. demonstrate, subtle changes in tumor
growth rate are not evaluated as a response when applying RECIST 1.1 criteria nevertheless, they do represent a true
cytostatic effect of targeted therapies that may translate into a meaningful prolonged survival.
11. SGR is a useful tool to identify subtle drug-associated tumor or
marker kinetic changes of tumors
Mehrara, as part of his PhD thesis at the Department of Radiation Physics, University of
Gothenburg, Goteborg, Sweden presented an analysis of tumor growth kinetics based on the
tumor specific growth rate constant (SGR). The analysis assumes that for most practical pur‐
poses clinically observable tumor growth follows exponential growth. Additionally, this is
true for the surrogate PSA tumor marker. SGR is rapidly calculable by hand-held mobile de‐
vices and facilitates the rapid identification of tumor responses easily overlooked in the clin‐
ic, many of which are not readily apparent without computer analysis. Occasionally,
changes of SGR uncover subtle tumor stimulation.
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Construction of the exponential growth curve, similar in shape to the mid portion of the
Gompertzian curve Figure 1, requires just two different measurements of tumor volume (or
diameter, area, cell number) or a surrogate marker at two different times to satisfy the expo‐
nential growth equation:Vt =V 0 e at  . Here “α” is the exponential growth constant, and Vt
and V0 are the tumor volume at times t and t0, respectively. This model implies that tumor
volume can increase indefinitely and the growth rate of a tumor is proportional to its vol‐
ume and dV/dt =aV .
SGR is the relative change in tumor volume per unit time calculable as percent increase or
decrease of tumor volume per unit time. Excluding mutations, for exponentially growing tu‐
mors, SGR is constant, i.e., SGR or α is independent of tumor volume or age. Faster growing
tumors have higher SGR values, SGR=0 represents non-growing tumors; a negative SGR
represents tumor regression. In 1956 Collins et al. [9] graphically introduced the concept of
tumor doubling time. The DT formulation was proposed in 1961 [10]: DT = (t2-t1) * ln(2) /
[ln(V2/V1)]. Other relationships of importance include the specific growth rate, SGR =
ln(V2/V1)/(t2-t1) and DT = ln(2)/SGR. These equations are descendants of the primary expo‐
nential growth equation, Vt = V0eat
Mehrara expresses concerns based on his mathematical treatment of SGR and DT suggesting
that for clinical studies, SGR is the best indicator of tumor growth. Tumor growth rate, espe‐
cially but not limited to urology circles, is usually quantified as DT i.e. PSA-DT. Because of
the subtle mathematical relationship between SGR and DT, use of DT alone to evaluate ther‐
apeutic effects may give erroneous results.
Mehrara’s studies revealed that DT has several drawbacks when used to describe tumor or
tumor marker growth rates. The shortfalls include 1) for brief measurement time intervals,
or high volume and very small measurement uncertainties the mean DT can either overesti‐
mate or underestimate the average growth rate; 2) DT approaches infinity for very slow
growing tumors and is mathematically limited while SGR is a continuous variable no mater
the speed and 3) the non normal frequency distribution of DT values restricts use of para‐
metric statistics thus reducing use of more discriminatory statistics especially when study‐
ing small samples [77]. Unlike DT, SGR is definable for all tumor volume changes no matter
how small, and it is Gaussian (normally) distributed allowing use of parametric statistics.
SGR is more accurate to use when considering growth fraction, cell loss rate, and tumor
growth rate heterogeneity. For these reasons, Mehrara opines that SGR be used instead of
DT, to quantify tumor growth rate.
Accuracy and clinical outcome analysis comparing SGR and DT would be a valuable area of
research in light of the cytostatic changes leading to subtle changes of growth rate character‐
istic of targeted therapies. Later, an in depth illustration of the differences between DT and
SGR will help illuminate this issue.
Collins and Schwartz [9, 10] both analyzed several tumors in patients as they defined the
use of tumor volume doubling time. Note that for bronchogenic lung cancers a semi-loga‐
rithmic plot of tumor diameter (y-axis) versus a linear time period (x-axis) produces a near
straight line Figure 2.
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12. Measuring tumor growth
It is imperative to depend on sensitive and precise marker assays. Guess [38] tried to ad‐
dress this problem by use of splines or line segments to average all PSA-DT values in an at‐
tempt to better detect therapy-induced changes of PSA-DT. Unfortunately, this
computerized technique is cumbrous for most to apply.
The accurate and reproducible measurement of tumor diameters from imaging studies is
critical. Keep in mind that occasionally plain radiographs of larger lesions are preferred be‐
cause CT imaging may slice through a lesion at variable levels producing aberrant results
for elliptical lesions.
A closer look at differences between DT and SGR.
The mathematical relationship between DT and SGR as revealed by the exponential growth
model is important because as displayed in Figure 10, sole use of tumor volume doubling
time (TV-DT) or tumor marker doubling time (PSA-DT) rather than tumor or marker specif‐
ic growth rate as a measure of treatment outcome may be destined for failure depending on
the magnitude of differences in the clinical study. Applying the exponential model of tumor
growth to published studies reporting only DT as displayed here Table 1,2 and Figures 11,12
reveals discordant conclusions from those using SGR. Note that the DT is mathematically
logarithmically related to the inverse of the exponential growth constant (SGR): SGR =
ln(2)/DT.
The opposite results using SGR compared to those obtained with DT are critical since pros‐
tate cancer research is steeped in the use of the PSA-DT to predict survival, tumor dissemi‐
nation, relapse, and tumor response to drugs and hormones and to radiation efficacy. In the
prostate cancer literature use of DT as a parameter of response is established canon.
Mehrara reveals that DT is not normally symmetrically distributed (non-Gaussian distribu‐
tion) and its use as an indicator of treatment response could yield inaccurate conclusions.
Changes in DT over-predict drug effects in slow growing tumors while they under-predict
in rapidly growing tumors and DT is essentially of no value for tumor volumes (or markers)
that show no change in value (stable disease) where DT approaches infinity see Figure 10.
Work by others confirms the importance of the tumor or marker-specific growth rate. Stein
et al. [46] studied a combination of equations that simultaneously modeled both tumor/ PSA
regression and tumor/PSA exponential growth. They found that only the exponential
growth equation with its specific growth rate constant (PSA-SGR) predicted a statistically
significant high mortality hazard ratio of 5.14 (95% confidence interval, 3.10 - 8.52) in his
study group of patients with prostate cancer. The disease regression formula was unable to
predict patient mortality.
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13. Why PSA-SGR is more useful than PSA-DT
As noted in Figure 10, when SGR is fast and increases 1% from 4 to 5%/day, the doubling
time changes 1.3-fold from 4 to 3 days (a slight change). However, when the SGR is slower
and increases 1% from 1฀2%/d, doubling time changes four-fold from 69 to 17 days (a large
change). A DT of 1-day does not represent the same growth rate when the tumor is slowing
as when the tumor is rapidly growing. As the absolute value of SGR approaches zero, DT
approaches infinity and is of no practical use other than to say the tumor or marker is stable.
Because of the DT-SGR relationship at the extremes of tumor or marker growth, therapy-in‐
duced changes in doubling times at the extremes of SGR do not accurately represent the
magnitude of the impact of therapy.
Figure 10. This figure, modified from Mehrara [70], displays the variation of tumor volume doubling time or tumor
marker doubling time (DT) per unit change of tumor specific growth rate (SGR) based on:.
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14. Clinical application of DT and SGR: Discordant results
Mehrara retrieved data from two previously published clinical studies [70]. The first by
Guess et al. [38] Table 1 who studied the effect of modified citrus pectin (MCP) on PSA-DT
of 12 prostate cancer patients. Mehrara extracted data and analyzed for both PSA-DT and
PSA-SGR before and after therapy. The difference between PSA-DT before and after treat‐
ment was not found to be statistically significant by the paired t-test (p = 0.27). Nevertheless,
when transforming PSA-DT to PSA-SGR the difference before and after MCP treatment is
statistically significant by the paired t-test (p = 0.003) and nonparametric Wilcoxon matched
pairs signed rank test: p = 0.002. Thus, a therapy initially deemed ineffective by PSA-DT
analysis, when analyzed for a group of patients based on PSA-SGR proved to be highly sig‐
nificant Table 1.
Effect of modified citrus pectin (MCP) on PSA-DT and PSA-SGR
Patient
Before Rx
PSA-DT
(mo)
After Rx
PSA-DT
(mo)
Before Rx
PSA-SGR (%/mo)
After Rx
PSA-SGR (%/mo)
A 3.97 13.34 17.46 5.16
B 5.67 10.11 12.22 6.86
C 1.14 2.91 60.80 23.82
D 3.37 7.71 20.57 8.99
E 1.58 16.49 43.87 4.20
F 10.5 7.97 6.60 8.70
G 2.66 11.95 26.06 5.80
H 3.64 3.27 19.04 21.20
I 2.04 4.96 33.98 13.97
J 2.33 3.24 29.75 21.39
K 6.29 -155.49 11.02 -0.45
L 5.12 -645.51 13.54 -0.11
Nonparametric Wilcoxon matched pairs signed
rank: p = 0.42
Parametric Paired t-test p = 0.2704
Nonparametric Wilcoxon matched pairs signed
rank: p = 0.002
Parametric Paired t-test p = 0.0027
Table 1. Guess et al. [38] studied the effect of modified citrus pectin (MCP) on PSA-DT of 12 prostate cancer patients.
Mehrara extracted that data and analyzed both PSA-DT and PSA-SGR before and after therapy. The difference
between PSA-DT before and after treatment was not statistically significant by the paired t-test (p = 0.27).
Nevertheless, when transforming PSA-DT to PSA-SGR the difference before and after MCP treatment is statistically
significant by the paired t-test (p = 0.003) and nonparametric Wilcoxon matched pairs signed rank test: p = 0.002.
A second analysis of original data by Nishida et al. (1999) [78] was based on a study of the
correlation of tumor volume and the CA19-9 tumor marker of pancreatic cancer patients Ta‐
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ble 2. The correlation between CA19-9-DT and tumor volume-DT was statistically signifi‐
cant (p<0.0001). However, after converting tumor-volume-DT to TV-SGR and CA19-9-DT to
CA19-9-SGR, correlation between CA19-9-SGR and TV-SGR was no longer statistically sig‐
nificant (p>0.3). Since SGR is the preferred parameter, the initial analysis of Nishida may
benefit from a second look.
Relationship between CA19-9-DT and TV-DT vs. CA19-9-SGR and TV-SGR
Patient CA19-9 DT(Days)
Tumor-DT
(Days)
CA19-9-SGR
%/day
Tumor-SGR
%/day
A 8.3 34.8 8.4 2
B 39.7 44.6 1.7 1.6
C 46.3 34.5 1.5 2
D 36.5 21.2 1.9 3.3
E 30.4 47.7 2.3 1.5
F 67.1 112.8 1 0.6
G 44.7 70.6 1.6 1
H 24.7 18.4 2.8 3.8
I 42.7 50.6 1.6 1.4
J 137.5 231.6 0.5 0.3
K 42.3 39.3 1.6 1.8
Linear regression: r2 = 0.89
p < 0.0001
Linear regression: r2 = 0.09
p = 0.37
Table 2. This table displays the extracted data from Nishida’s study [78] of the correlation of tumor volume and the
CA19-9 tumor marker of pancreatic cancer patients. The correlation between CA19-9-DT and tumor volume-DT was
statistically significant (p<0.0001). However, after converting tumor-volume-DT to TV-SGR and CA19-9-DT to CA19-9-
SGR, correlation between CA19-9-SGR and TV-SGR was no longer statistically significant (p>0.3).
Most prostate cancer studies employ changes in the PSA-DT. PSA-DT values are not nor‐
mally distributed and thus not readily subject to more sensitive parametric statistical analy‐
sis. However, PSA-specific growth rate is normally distributed and parametric statistics can
be applied. Nonparametric statistical methods lose discriminatory power especially for clini‐
cal studies of smaller groups of patients [77].
During a cursory review of the literature we found two additional studies, one dealing with
the effects of celecoxib on PSA-DT Figure 11 and the other investigating the effects of a com‐
bination of calcitriol and naproxin on PSA-DT of prostate cancer patients Figure 12.
Smith et al. [79] Figure 11 studied the biologic activity of celecoxib, a selective cyclooxyge‐
nase-2 inhibitor, in men with recurrent prostate cancer using change in PSA-DT as the pri‐
mary outcome variable. We carefully extracted the data from his graphic report. We applied
the Wilcoxon matched-pairs signed rank test [two tailed] (for nonparametric distribution of
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PSA-DT) to the data. PSA-DT before versus after celecoxib was highly significant: p = 0.0006.
After transformation of PSA-DT to PSA-SGR, the Paired t-test [two tailed] for parametric dis‐
tribution of PSA-SGR suggests that the celecoxib effect lacked statistical significance p = 0.213!
A second study by Srinivas [80] Figure 12 evaluated naproxen in combination with calcitriol
in patients with early recurrent prostate cancer. All patients received 45 μg of calcitriol
(DN101, Novacea, South San Francisco, CA, USA) orally once a week with naproxen 375 mg
twice a day and were evaluated for a biochemical PSA response and a change in PSA dou‐
bling time (PSA-DT). Testing the efficacy of the combination therapy using changes of PSA-
DT by the non-parametric Wilcoxon matched-pairs signed rank test [two tailed] p = 0.037 a
significant difference. However, after transforming PSA-DT to PSA-SGR (SGRPSA = ln(2)/
DTPSA), analysis with the parametric Paired t-test [2-tailed] indicate naproxen plus calcitriol
was not effective in slowing tumor growth, p = 0.213.
Figure 11. Smith et al. [79] studied the biologic activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in men
with recurrent prostate cancer using change in PSA-DT as the primary outcome variable. We retrieved their graphic
data for our own analysis. A histogram of the PSA-DT paired differences for before and after celecoxib appears nor‐
mally distributed. Applying the parametric Paired t-test statistic for significance of the difference yields p = 0.0002.
Next, we transformed the same (before-after celecoxib PSA-DT data with to PSA-SGR before and after pairs and ap‐
plied the paired t-test. Contrary to the statistical analysis for celecoxib induced change of PSA-DT, changes of PSA-SGR
revealed that the celecoxib difference was no longer significant, p = 0.213!
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Figure 12. Sinivras and Feldman [80] evaluated naproxen in combination with calcitriol in patients with early recur‐
rent prostate cancer. All patients received 45 μg of calcitriol (DN101, Novacea, South San Francisco, CA, USA) orally
once a week with naproxen 375 mg twice a day and were evaluated for a biochemical PSA response and a change in
PSA doubling time (PSA-DT). Applying the paired t-test for statistical significance (before PSA-DT and after PSA-DT)
resulted in p = 0.034. Nevertheless, after transforming PSA-DT to PSA-SGR (PSA-SGR = ln(2)/PSA-DT), analysis with the
paired t-test [2-tailed] suggested naproxen plus calcitriol was not effective in slowing tumor growth, p = 0.213.
The non-linear relationship between the SGR and DT may be responsible for erroneous in‐
terpretations of treatment effects reported in prior prostate cancer trials that published re‐
sults solely in terms of changes in PSA-DT Figure 10.
15. Evaluation of tumor and surrogate marker drug responses, rate of
change of response:
SGR acceleration = (SGR after Rx −  SGR before Rx) / (t2− t1) ; A positive
number
The dynamic of PSA change was used as an early predictor of overall survival after a short
exposure to docetaxel therapy (4 doses). Knowledge that a drug may extend survival after
just a short exposure would minimize toxicity from ineffective drugs. Hannenin‘s work [81]
found that a rapid rate of PSA decline expressed as PSA half-life <70 days was associated
with a longer overall-survival Figure 13. This result was independent of other known mark‐
ers of survival and allowed for a greater survival differentiation than PSA suppression
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alone. Response-time evaluations may play a new role in determining drug efficacy earlier
than usual. I would propose study of an alternate expression for tumor acceleration or decel‐
eration in terms of SGR as: SGR (accel…decal) = SGR2-SGR1/(t2-t1). The value of this expres‐
sion may be positive for acceleration or negative for deceleration.
De Crevoisier [82] found that a PSA decline 6 weeks after the start of EBRT when used as
monotherapy and 3 months after the start of androgen deprivation therapy (ADT) in pa‐
tients treated with combined ADT and external beam radiation is predictive of progression
and specific survival.
Figure 13. Treatment-associated tumor/marker deceleration in response to docetaxel. The magnitude of rate of
change (acceleration-deceleration) of SGR resulting from therapy is an early predictor of prostate-specific survival.
Figure 14 illustrates a computer analysis of a prostate cancer patient treated with docetaxel. A
pelvic node is noted to grow over 4.5 months from 1.3 to 1.6 cm in greatest dimension. This es‐
tablishes the pre-therapy SGR of 0.46%/d and the tumor volume (assuming a sphere) before
starting therapy is 2.1 cc. Fifty-one days of therapy induces a decrease of tumor diameter to 0.9
cc and a decrease of tumor volume to 0.38 cc. Had the tumor grown uninterrupted the project‐
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ed tumor volume would have been 2.7 cc. In this case, the value for deceleration of SGR for the
tumor: is given as (SGR2 after Rx −  SGR1 before Rx) / (t2− t1) =−0.021% / d / d .
Figure 14. This calculation displays results for a patient treated with docetaxel (see text).
This is an objective measure of the rate of change of SGR. The treatment response is dis‐
played as = + 2.0. This assigns a calculated continuous variable as a measure of the degree of
response and is used to objectively compare docetaxel efficacy to any other administered
drug. Positive TR values represent tumor reduction compared to the projected tumor size
while a negative TR represents tumor growth relative to the projected size. Estimated age of
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tumor, here approximated ~ 12.3 years, is a calculated value based on the initial SGR of
0.46%/d in the absence of therapy. This assumes constant, continuous exponential growth
over many years. Tumor age calculations are gross approximations and notoriously subject
to large error.
Figure 15 illustrates the evaluation for a 68 year-old man undergoing watchful waiting for a
Gleason score 3+3 = 6, T1c prostate cancer. Three PSA values are displayed for three sequen‐
tial dates. When the patient was asked if he had changed medication between 3/2/11 and
5/1/11 he noted he was ingesting a new Chinese herbal mixture sold to enhance energy and
libido.
Figure 15. Evaluation of a 68 year-old man undergoing watchful waiting for a Gleason score 3+3 = 6, T1c prostate
cancer. The patient was ingesting a stimulatory Chinese herb.
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Subtle acceleration of the tumor marker value was uncovered by inspection of the projected
PSA value for 5/1/11 as compared to the actual measured value for that date. Notice the con‐
firmative quantitative measures given by the calculation Figure 14 of the marker specific
growth rate MSGR2 = 0.13%/d compared to MSGR1 = 0.07 %/d; marker doubling time MDT2
= 17.3 months compared to the initial MDT1 = 30.9 months; by both the positive value for
MSGR acceleration = +0.001%/d/d and by the negative value for marker response MR = -
0.05. Based on the marker-specific growth rate (MSGR) for the first interval TDx thru TPRx
(the date at initiation of therapy) of 0.07%/d, the App calculated the expected PSA on 5/1/11
to be 5.98 ng/ml. However, the measured value was higher = 6.3 ng/ml. The negative value
for MR of -0.05 indicates a negative marker response thus PSA expansion (marker accelera‐
tion confirmed this = +0.001%/d/d). We suspected that the Chinese herb might have caused
subtle acceleration of PSA production and or tumor growth. Other explanations for accelera‐
tion of the PSA value include decreased clearance of PSA or the subtle appearance of a mu‐
tated, faster growing clone of PSA-producing tumor cells. Note that in the absence of
knowledge of the inherent initial PSA-SGR between 2/1/11 and 3/2/11 and calculation of the
expected projected value of PSA for 5/1/11, the subtle PSA acceleration would have been
missed.
16. Predicting approximate tumor size or marker value for any arbitrary
date in the future
Assuming untreated clinical cancers and their markers expand at a relatively constant expo‐
nential rate, it is possible to predict values for tumor diameter, volume and marker for any
arbitrary future date. Figure 16 displays a PSA projection made for a patient with newly di‐
agnosed prostate cancer who asked if a preplanned three-month holiday before initiation of
therapy could jeopardize his chance for a curative procedure. The prediction, assuming con‐
stant exponential expansion of serum PSA, is that the PSA value upon returning from sab‐
batical would increase from 9.4 to 16.28 ng/ml. This alarmed the patient and he cancelled the
trip to initiate therapy.
17. Unique treatment paradigms may be suggested by analysis of tumor
growth rate
Figure 17 illustrates results for a patient with pancreatic cancer post Whipple procedure
who was found on 6/4/10 to have an enlarged peri-aortic mass = 1.8 cm (3.1 cc). Repeat CT
on 8/27/10 noted increased size to 2.9 cm (12.8 cc). Therapy with gemcitabine was initiated
on 8/27/10. Post therapy reevaluation of the mass on 12/24/10 revealed growth to 3.1 cm
(15.6 cc). The patient was discouraged and frightened and thought he had wasted precious
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time and subjected himself to undo toxicity for no gain. However, evaluation revealed that
had the tumor never been treated with gemcitabine it would have reached the projected
volume of 96.9 cc by 12/24/10. Thus, based on the initial exponential growth rate from 6/4/10
thru 8/27/10, the tumor volume was actually 84% less than what it would have been had no
drug been given (15.6 cc vs. 96.9 cc).
This patient experienced substantial tumor suppression by gemcitabine in spite of its
growth. Under these circumstances, when there are poor second choices for effective thera‐
py, instead of discarding gemcitabine, perhaps addition of another compound with differing
toxicity might be a reasonable option.
Figure 16. PSA projection made for a patient with newly diagnosed prostate cancer
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Figure 17. The tool we developed to facilitate calculation of tumor kinetics is named CancerPal©. The software App is
available from Apple Corporation’s App store. The App analyzes kinetic changes of tumor markers and or tumor diam‐
eter/volume/area and is run on the iPhone, iPad, or iPod. Clinical use is facilitated by the small size and portability of
the new hand-held devices. The App is routinely used in our clinic for objectively measuring subtle drug effects on
tumor and the dynamics of surrogate tumor markers. A video tutorial of the App is available at www.healthsciencere‐
ports.com.
18. Conclusion
Several principles of prostate cancer management rely on the absolute and dynamic values
of various formulations of PSA i.e. PSA-V, PSA-DT and PSA-SGR. This review introduces
SGR, a parameter that is underused and closely reflects the true growth rate of tumors un‐
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dergoing exponential expansion. Several instances are presented where results of studies
employing PSA-DT yield statistically divergent results after converting PSA-DT to PSA-
SGR. It is recommended that for some studies results be reevaluated in terms of PSA specific
growth rate, PSA-SGR.
Newly introduced targeted therapies require innovative techniques to evaluate drug effica‐
cy. Tumor or tumor marker specific growth rate and the concept of projected tumor or
marker value are tools capable of quantitatively evaluating subtle effects of targeted drugs.
Calculation of the projected tumor size and tumor marker values is critical to properly eval‐
uate subtle drug-tumor proliferative outcomes.
Appendix
CancerPal©
It is important to realize that CancerPal© remains an experimental tool used strictly for anal‐
ysis of clinical and laboratory data by cancer researchers, pharmacists or clinical research ra‐
diation and medical oncologists. The methods used in designing this tool have been
discussed primarily in the references listed below with special attention given to the work of
Mehrara et al. PNA, A Limited Liability Corporation, cannot be held responsible for any
treatment modifications or recommendations made based on this research tool.
What CancerPal© does
CancerPal© evaluates whether a chemotherapy or targeted therapy should be continued
alone, possibly dropped or added to by revealing concealed drug activity causing suppres‐
sion of the tumor specific growth rate. The app uncovers occult efficacy of drugs by compar‐
ing the measured drug-induced tumor size vs. the projected tumor size or projected tumor-
marker value that would occur in the absence of any therapy. Sudden changes in tumor
growth rate suggesting drug related tumor stimulation or a detrimental, growth-promoting
mutation is rapidly identified. CancerPal© may uncover hidden tumor acceleration unex‐
pectedly caused by drugs, immunosuppression or alternative therapies thought to be harm‐
less
CancerPal© uses a tumor’s specific growth rate (TSGR) defined as percentage increase in vol‐
ume per day or percentage increase in the specific tumor marker per day thus avoiding er‐
rors inherent in the doubling time calculation which consistently overestimates the growth
rate of slowly growing tumors and underestimates the growth rate of rapidly growing tu‐
mors.
This app predicts the tumor diameter or tumor marker value at any time in the future as‐
suming constant exponential tumor or tumor marker growth over the period of observation.
This, when compared to the actual measured tumor diameter or marker value, identifies tu‐
mor response, stability or acceleration. The app predicts a tumor marker or diameter at any
time point in the future based on patient-specific tumor kinetics. CancerPal© may quickly
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alert the clinician of emergence of a mutant, more aggressive, rapidly dividing clone of tu‐
mor cells suggesting a review of therapy. Analysis based on continual exponential growth
for the relatively short time (several months) in the multi-year history of tumor growth has
been found to be more useful for kinetic calculations in spite of some tumors demonstrating
Gompertzian growth over the long haul (several years)
Continuous variables for Tumor Response (TR) and Marker Response (MR) allow for quan‐
titation of drug/biological response modulator effects. Negative values of TR and MR indi‐
cate tumor acceleration, values close to or equal to zero indicate lack of response while
positive values confirm beneficial tumor response. Responses are numerically quantitated
and elusive disease stability may now numerically be defined by a continuous variable.
Drugs previously thought to be of no value may be found to induce useful and profound
disease stability
The software is helpful for those patients followed by watchful waiting/active surveillance
for prostate or any other cancer. Prostate tumors changing biological behavior are immedi‐
ately identified in a quantitative and objective manner by rapidly uncovering changes in
PSA kinetics without the errors inherent in the PSA doubling time (PSA-DT) parameter. The
software can help determine whether metastectomy is a reasonable treatment modality for
some patients with pulmonary metastasis [83].
CancerPal© uses the exponential growth constant as described by John Spratt to extrapolate
backwards to approximate the time of tumor initiation in years based on the rate of growth
Patient data required for analysis
Three dates and three associated measurements of a tumor marker or tumor diameter
• TDx (date at diagnosis + marker value or tumor diameter in cm)
• TPreRx (date of initiation of Rx + marker value or tumor diameter in cm)
• TPostRx (date of measurement of drug effect + tumor marker value or diameter in cm).
CancerPal© information output:
• Tumor Specific Volume Growth Rates for two intervals (TSGR1 and TSGR2)
• Tumor Marker Specific Growth Rates for two intervals (MSGR1 and MSGR2)
• Tumor Specific Growth Rate acceleration and deceleration
• Tumor Volume Doubling Times for two intervals (TVDT)
• Tumor Marker Doubling Time for two intervals (MDT)
• Projected TSGR and MSGR at any user designated time in the future
• Treatment Response as both Tumor Response and Tumor Marker Response, both as con‐
tinuous numerical values used to quantitate the effect of therapy. Negative numbers re‐
veal growth acceleration; values of zero reveal no effect and positive values indicate
varying degrees of therapeutic efficacy.
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• Tumor volumes in cc are calculated for TDx, TPreRx and TPostRx.
• Extrapolates back to the time of tumor initiation thus calculating how long it took for the
tumor to reach the initial tumor diameter.
• Calculates approximate time to death in the absence of therapy, assuming constant tumor
growth rate.
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